European Medicines Agency Released Its “Brexit Preparedness Business Continuity Plan” 16th October 2017
The plan aims to safeguard continuity of EMA’s operations to protect public health while the Agency prepares for its relocation to a new host city and the departure of the United Kingdom from the European Union (EU). EMA’s Business Continuity Plan is an essential tool to deal with the uncertainty and workload implications linked to the UK’s withdrawal from the EU and the Agency’s relocation.
It describes the methodology by which EMA has categorised and prioritised its activities and how it plans to reallocate resources to its core activities if needed. The plan prioritises tasks and activities and classifies them into three categories (page 4) according to their impact on public health and the Agency’s ability to function.
It should be noted that the physical move to the new EMA seat will require a second BCP to be invoked addressing business continuity before, during and after the physical move. Such second BCP, the EMA Relocation BCP, will be developed once the decision on the location of the new EMA premises has been taken and more information is available on the timetable for relocation to the new host MS.
The 17-page document is available at: